Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

 
Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors

Colby drugs resore therapy-sensitivity or normoxia
Kenneth W. Narducy, PhD, MBA

Chairman of the Board

Ken Narducy is also currently President and a Director of St Charles Pharmaceuticals, a private pharmaceutical company.

Prior to this time, he was employed as VP and General Manager, Centaur Pharmaceuticals Inc, Executive VP and President/Executive Vice President at Oculex Pharmaceuticals, Vice President of Research and Development at CooperVision Ophthalmic Products; Director of Research and Development at Wesley-Jessen; and Manager of Research and Development at Abbott Laboratories.

Dr. Narducy has many years of drug development experience and is a highly regarded and effective senior manager, pharmaceutical executive and physical organic chemist. Dr. Narducy has been a pharmaceutical expert and executive for many years. Previously, he has been a key manager and scientist at nine companies involved in the development and commercialization of therapeutic drugs and ophthalmic products.

The value of Dr. Narducy's previous business transactions exceeds $1B.

Dr. Narducy holds a Ph.D. in Physical Organic Chemistry from Ohio State University and an MBA in Marketing & Finance from the University of Chicago.